covid-19 pneumonia

Xortx Therapeutics to assess XRx-101 for Covid-19 treatment

Reading now: 274
www.pharmaceutical-technology.com

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Xortx Therapeutics is set to explore XRx-101, a formulation of Oxypurinol, as a potential treatment for acute kidney and lung injury associated with Covid-19.

Analysis of recent studies revealed that the most severe Covid-19 cases are characterised by acute kidney injury and acute pulmonary injury.

Furthermore, coronavirus infections involve pneumonia, acute kidney injury, proteinuria and haematuria. Based on the studies, Xortx Therapeutics believes that XRx-101 possesses the potential for front-line treatment of severe coronavirus cases while reducing morbidity and mortality in hospitalised patients.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA